The clinical trials will be conducted at Zydus Research Centre, which is equipped to conduct the initial trial.
Extensive pre-clinical studies on ZYHl indicated that it might be free from the side effects that are seen with the glitazones, fibrates and statins, which are currently used in the treatment of dislipidemia and glucose intolerance.
The formula has the potential to correct dyslipidemia, improve insulin resistance and lower blood glucose in diabetic mellitus and metabolic syndrome, it said.
"ZYH1 is expected to address the issue related to patients suffering from dyslipidemia in both diabetic and non-diabetic ondition", said B B Lohray, president, Zydus Research Centre.
